ImmunityBio, Inc.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$38M
↑+407.0% +$31Mvs FY2024 (Q4)
Gross Profit
$38M
↑+401.9% +$30Mvs FY2024 (Q4)
Operating Income
$34M
Net Income
$19M
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $38M | $8M |
| COGS | $382K | $0 |
| Gross Profit | $38M | $8M |
| R&D | $0 | $35M |
| SG&A | $0 | $42M |
| D&A | $4M | $4M |
| Other OpEx | $0 | $0 |
| Operating Income | $34M | $0 |
| Interest Exp. | $15M | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $19M | $0 |
| Tax | $0 | $0 |
| Net Income | $19M | $0 |
QuarterCharts · SEC EDGAR data · IBRX · Comparing FY2025 (Q4) vs FY2024 (Q4)